RxDoctor Payments Data

Barry Weinstock, MD

Interventional Cardiology · Altamonte Springs, FLNPI 1548213200

Payments from drug & device makers

$179,861in general payments, 2019–2025

Across 686 payments — averaging $262.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$59K
  • Stryker$26K
  • Penumbra, Inc.$19K
  • Boston Scientific$16K
  • Angiodynamics, Inc.$15K
  • Idev Technologies, Inc.$8K
  • plus $37K from 54 others
$2,500in research payments, 2019–2025

Across 1 payment — averaging $2500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Atrium Medical Corporation$3K

What the payments were for

  • Royalty or licence$49,36832%
  • Consulting fees$21,02513%
  • Speaking & faculty fees$8,5255%
  • Travel & lodging$12,3288%
  • Food & beverage$37,38424%
  • Education$3,1512%
  • Ownership interest$24,33016%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)59$58,799
Stryker(2 entities)27$25,787
Penumbra, Inc.52$18,611
Boston Scientific6$16,476
Angiodynamics, Inc.2$15,056
Idev Technologies, Inc.1$8,100
Inari Medical, Inc.71$7,536
Abiomed8$6,556
Abbott142$5,466
Biotronik Inc.86$4,490
Cvrx, Inc.48$3,442
W. L. Gore & Associates, Inc.4$1,652
Siemens Medical Solutions USA, Inc.6$859
Terumo Medical Corporation3$652
Philips North America LLC6$573
Intact Vascular, Inc.2$512
Amgen27$497
Novartis19$339
Cardiovascular Systems Inc.6$332
Impulse Dynamics (USA) Inc.5$279
Pfizer10$273
ZOLL Respicardia, Inc.1$239
Cook Medical LLC3$236
Celonova Biosciences, Inc.2$222
Cardiva Medical, Inc.3$197
Imperative Care, Inc3$191
Johnson & Johnson4$171
Teleflex LLC9$171
Kestra Medical Technology Services, Inc.4$170
Thrombolex, Inc.1$160
Inspiremd Ltd1$159
Limflow Inc.1$156
Contego Medical, Inc1$140
Venclose Inc.1$125
Boehringer Ingelheim2$117
Amarin Pharma, Inc.7$116
United Therapeutics Corporation1$110
Esperion Therapeutics, Inc.4$104
E.r. Squibb & Sons, L.L.C.6$101
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)4$87
Regeneron Healthcare Solutions, Inc.4$84
Sanofi-aventis U.S. LLC5$82
Merck4$81
Corindus Inc.1$70
Nuwellis, Inc.2$46
Bayer2$37
Edwards Lifesciences1$25
AstraZeneca1$24
Atricure, Inc.1$23
Akcea Therapeutics, Inc.1$21
Braemar Manufacturing, LLC1$19
Cashflow Solutions, LLC1$15
Avantec Vascular Corporation1$15
Organogenesis Inc.1$14
ZOLL Circulation Inc1$13
Livanova USA, Inc.1$13
Cardinal Health 200 LLC1$12
Tactile Systems Technology Inc1$11
Ablative Solutions, Inc.3$0
Verge Medical, Inc.5$0

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$179,861 in reported general payments places this provider in the 85th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$543,905
Medicare patients
893
Services billed
4,111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban351$382,670
EntrestoSacubitril/Valsartan82$104,508
Repatha SureclickEvolocumab86$83,285
XareltoRivaroxaban68$66,516
JardianceEmpagliflozin33$54,563
Praluent PenAlirocumab35$25,679
BrilintaTicagrelor33$22,153
MounjaroTirzepatide14$14,635
Ranolazine ErRanolazine36$6,989
Ezetimibe208$3,994
Valsartan99$3,769
Rosuvastatin Calcium303$3,755
Atorvastatin Calcium400$3,581
Metoprolol Succinate206$3,330
ClopidogrelClopidogrel Bisulfate255$2,603

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$273$382,670351 claims
NovartisEntresto$339$104,50882 claims
Johnson & JohnsonXarelto$171$66,51668 claims
Boehringer IngelheimJardiance$117$54,56333 claims
AstraZenecaBrilinta$24$22,15333 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Altamonte Springs

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →